Covered recipient · General Payments record
JOEL A GORN
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$2,846.58
- Reported across 140 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $343.18 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $107.44 | 5 |
| Sumitomo Pharma America, Inc. | $57.63 | 2 |
| Amgen Inc. | $37.13 | 2 |
| Acerta Pharma LLC | $36.85 | 2 |
| SHIELD THERAPEUTICS INC | $23.66 | 1 |
| Abbott Laboratories | $21.07 | 1 |
| Otsuka America Pharmaceutical, Inc. | $20.81 | 1 |
| Lilly USA, LLC | $19.74 | 1 |
| Novo Nordisk AS | $18.85 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $21.07 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124908706 | CMS |
| ABBVIE INC. | $18.37 | 01/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103823074 | CMS |
| ABBVIE INC. | $27.55 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103823076 | CMS |
| ABBVIE INC. | $21.71 | 03/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103823078 | CMS |
| ABBVIE INC. | $22.06 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103823080 | CMS |
| ABBVIE INC. | $17.75 | 04/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103823082 | CMS |
| Amgen Inc. | $20.50 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111587462 | CMS |
| Amgen Inc. | $16.63 | 06/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111587464 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.26 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104470420 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.59 | 07/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105213090 | CMS |
| Lilly USA, LLC | $19.74 | 10/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135050518 | CMS |
| Novo Nordisk Inc | $18.85 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097324328 | CMS |
| Otsuka America Pharmaceutical, Inc. | $20.81 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118899994 | CMS |
| SHIELD THERAPEUTICS INC | $23.66 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150149991 | CMS |
| Sumitomo Pharma America, Inc. | $29.78 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148858001 | CMS |
| Sumitomo Pharma America, Inc. | $27.85 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148858003 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.